Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 45.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,521 shares of the medical research company's stock after selling 3,709 shares during the period. Tower Research Capital LLC TRC's holdings in Charles River Laboratories International were worth $835,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter worth about $601,000. JPMorgan Chase & Co. lifted its holdings in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after purchasing an additional 85,759 shares during the period. Veracity Capital LLC purchased a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $589,000. Lord Abbett & CO. LLC increased its holdings in Charles River Laboratories International by 5.8% in the 3rd quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company's stock worth $21,413,000 after buying an additional 5,959 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after buying an additional 47,221 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on CRL. Barclays dropped their price objective on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird cut their price target on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their target price for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, Mizuho reduced their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and an average target price of $182.00.

Insider Activity

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO James C. Foster purchased 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

NYSE CRL traded up $0.36 on Wednesday, hitting $117.65. The company had a trading volume of 464,710 shares, compared to its average volume of 1,513,215. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company has a market capitalization of $5.78 billion, a PE ratio of 784.33, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The company's fifty day moving average price is $144.83 and its 200-day moving average price is $170.07.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.46 earnings per share. As a group, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).